TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and ...
A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive ...
Bladder cancer recurs locally 30 per cent to 54 per cent of the time ... The charity Prostate Cancer UK has trained Relate counsellors in the specific challenges faced by prostate cancer patients.